Gossamer Bio submits first NDA for seralutinib in pulmonary arterial hypertension
Gossamer Bio submitted a New Drug Application to the FDA for seralutinib for pulmonary arterial hypertension, its first NDA filing.Key Highlights:Original SEC Filing: Gossamer Bio, Inc. [ GOSS ] - 8-K - Sep. 23, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impo…